Burimamide
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Names | |
|---|---|
| IUPAC name
1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
|
|
| Identifiers | |
34970-69-9  |
|
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL12160 |
| ChemSpider | 2297780 |
| KEGG | C07448 |
| PubChem | 3032915 |
| UNII | TN5A4OD2TV |
|
|
|
|
| Properties | |
| C9H16N4S | |
| Molar mass | 212.32 g/mol |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
 verify (what is  ?) |
|
| Infobox references | |
Burimamide is an antagonist at the H2 and H3 histamine receptors. It is largely inactive as an H2 antagonist at physiological pH,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).[2]
See also[edit]
References[edit]
- ^ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
- ^ a b "Tagamet®: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012.
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
